Medivir appoints vp for r&d projects


Charlotte Edenius takes up newly created position

Medivir, a Swedish research-based specialist pharmaceutical company focused on infectious diseases, has appointed Charlotte Edenius to the new position of vice president, research & development projects.
Charlotte Edenius

Charlotte Edenius

Sign up for your free email newsletter

Edenius holds a medical degree and has a PhD from the Karolinska Institute. She joined Medivir this month from Swedish pharmaceutical company Orexo, where she was senior vice president and chief scientific officer.

Prior to this, Edenius was vice president and chief scientific officer of Biolipox from 2001–2007 and held various executive positions in experimental medicine, Clinical R&D at AstraZeneca in Sweden.

Medivir’s key pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical development for Hepatitis C and is partnered with Tibotec Pharmaceuticals.